Royce M, Shah M, Zhang L, Cheng J, et al. FDA Approval Summary: Datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer. Clin Cancer Res 2025 Aug 27:10.1158/1078-0432.CCR-25-1388.
PMID: 40864501